Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cree, Inc.    CREE

Delayed Quote. Delayed  - 05/27 09:59:59 pm
24.06 USD   +0.12%
05/24 CREE : Extends Groundbreaking OSQ Series to Deliver 58 Percent Effic..
05/24 CREE : Extends Groundbreaking OSQ Series to Deliver 58 Percent Effic..
05/17 CREE : to Webcast Upcoming Conference Presentation
Analysis summary4-Traders Strategies 

Cree, Inc. : End of the technical recovery

share with twitter share with LinkedIn share with facebook
share via e-mail
11/09/2012 | 03:13pm
Opinion : Bearish under USD 32.1
Target price : USD 28.6
Stop loss: USD 33.8

The share is meeting an important level. We suggest caution because this point could stop the bullish trend.

From a fundamental viewpoint, firstly, we note the high valuation of the company. PER for the current year is at 46.44x and expected at 26.93x for next year. With a valuation ratio of 2.2x, the group appears overvalued compared to its business activity.

From a technical viewpoint, the proximity of the USD 32.1 medium-term resistance limits the upside potential on the stock. The uptrend in the short term could be stopped by this level and prices could decrease sharply in the coming sessions. Technical indicators also show an overbought situation that reinforces this bearish scenario. Thus, there is a higher downside potential than upside.

The graphical configuration argues to establish a short position at the current price. The end of the technical rebound, the consolidation phase and overbought situation, there are all the characteristics for short selling. The first objective will be fixed near the USD 28.6 short term support and by extension the USD 22.8 area. This strategy should be protected by a stop loss above USD 32.1.

Cree, Inc. : Cree, Inc. : End of the technical recovery

© Zonebourse.com 2012

share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: 4-traders.com is a website published by SURPERFORMANCE SAS. Surperformance or 4-traders.com is not a registered broker-dealer nor a registered investment adviser. You understand that this web site and its content is furnished for your personal, noncommercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold any other security, nor that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Surperformance and 4-traders.com services will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. Information regarding trading and investment as provided by Surperformance professional is not tailored to the investment needs of any specific person. You acknowledge that you are responsible for your own financial decisions and should seek a registered financial agent depending on your own risk tolerance to advise you on your personal trading activities.

Financial Ratios

Size 2016e 2017e
Capitalization 2 416 M$ -
Entreprise Value (EV) 1 949 M$ 1 893 M$
Valuation 2016e 2017e
P/E ratio (Price / EPS) 70,6x
Capitalization / Revenue 1,50x 1,41x
EV / Revenue 1,21x 1,11x
EV / EBITDA 8,60x 7,37x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 1,04x 1,00x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 6,44% 7,19%
operating Leverage (Delta EBIT / Delta Sales) - 3,03x
Net Margin (Net Profit / Revenue) -0,50% 1,69%
ROA (Net Profit / Asset) -1,30% -0,70%
ROE (Net Profit / Equities) 0,61% 0,49%
Rate of Dividend - -
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   8,41% 8,87%
Cash Flow / Sales 14,8% 13,8%
Capital Intensity (Assets / Sales) 0,38x -2,42x
Financial Leverage (Net Debt / EBITDA) -2,06x -2,04x
Income Statement Evolution
More Financials
EPS Revisions